Redcare Pharmacy Faces Dual Challenges as Key Payment and Rival Expansion Loom

The start of 2026 presents a period of significant pressure for online pharmacy operator Redcare Pharmacy. The company’s shares have shed nearly half their value over the past twelve months, and two critical challenges are converging: a substantial bond repayment and an aggressive new competitor entering its core market.

A Major Competitor Enters the Fray

The competitive landscape shifted fundamentally in mid-December 2025. German drugstore chain dm-drogerie markt launched its “dm-med” platform on December 16, making a targeted move into the over-the-counter (OTC) medication market. This segment has been a traditional revenue stronghold for Redcare.

dm-drogerie markt enters from a position of strength, boasting an existing base of 12.5 million app users and a network of approximately 4,200 physical stores to support logistics. The retailer has also announced intended price advantages of 20 to 30 percent compared to traditional pharmacies. This poses a direct threat to Redcare, which is already operating on thin margins. The company’s adjusted EBITDA margin stood at just 2.4% in the third quarter of 2025.

Strategic Pivot Toward Prescription Drugs

In response to this new competitive threat, Redcare’s management is executing a strategic pivot. The company is now focusing on accelerating its prescription (Rx) medication business, a segment where dm-drogerie markt is not currently active. This shift appears to be gaining traction; Rx sales surged by over 42% year-on-year to 272 million euros in Q3 2025, a growth partly driven by the introduction of Germany’s electronic prescription system.

To support this expansion and enhance delivery capabilities, particularly to Austria and Southern Germany, Redcare commissioned a new logistics center in the Czech Republic in December 2025.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

A Crucial Financial Deadline Approaches

Simultaneously, the company faces a pressing financial obligation. On January 21, 2026, Redcare must pay 64.5 million euros to bondholders who exercised their put option on the 2021/2028 convertible bond. This payment represents the final step in a broader refinancing initiative that included:
* The repurchase of 157.9 million euros of the original bond in April 2025.
* The issuance of new 300 million euro convertible bonds maturing in 2032, also in April 2025.
* Following the January payment, only 2.6 million euros of the old bond will remain outstanding.

The company’s liquidity position, reported at 265.6 million euros in liquid funds as of September 30, 2025, appears sufficient to cover this obligation, showing a notable increase from the 177.6 million euros held at the end of 2024.

Divergent Analyst Views and Short Interest

Market experts are sharply divided on the company’s outlook. Analyst recommendations vary widely:
* Deutsche Bank maintains a “Buy” rating with a price target of 214 euros.
* UBS expresses caution with a “Neutral” stance and a 74 euro target.
* Barclays recommends “Overweight” with a 130 euro price target.

Adding to the uncertain sentiment, short interest in Redcare shares remains elevated at approximately 14%, indicating persistent institutional skepticism.

The Ultimate Test Arrives in March

The period following the January bond payment will lead to a critical milestone. On March 4, 2026, Redcare is scheduled to release its full-year 2025 results and provide its outlook. This report will serve as the first clear indicator of the financial impact from dm-drogerie markt’s market entry on the OTC business and whether the company’s slim margins can be sustained. The success of its strategic bet on prescription medications will likely be a decisive factor for the equity’s future performance.